Pharma BD Deal Intelligence
A merger-of-equals that quietly built the platform behind Enhertu — one of oncology's defining drugs of the 2020s
Full analysis, sources & comparables →Former shareholders of Daiichi held approximately 42.0% and former shareholders of Sankyo held approximately 58.0% of the outstanding common stock of Daiichi…
Enhertu tripled sales and reached blockbuster status during Daiichi's 2022 fiscal year, while Vanflyta was approved in May 2023 for first-line AML.
Daiichi Sankyo was established in 2005 through the merger of Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Merger completes Sept 28, 2005 forming Daiichi Sankyo - Japan's #2 pharma by revenue.
A merger-of-equals that quietly built the platform behind Enhertu — one of oncology's defining drugs of the 2020s
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. (this deal) | 2005 | $8.0B | 92 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
← Browse all deals · How we score deals
More: 2005 deals